Roughly half of patients with long-term conditions — diabetes, hypertension, heart disease, COPD — don't take their medication as prescribed, and poor adherence is linked to a 63% higher risk of death in chronic-disease patients. That's the backdrop for a question worth asking honestly: does a medication reminder device actually move that number, or is it just a nicer pillbox?

A factorial randomized controlled trial set out to test exactly that, in the population where multi-drug regimens and adherence risk overlap the most: elderly patients with type 2 diabetes.

The trial design

120 elderly patients with type 2 diabetes were split across four arms: standard care alone, standard care plus MedpeR®, standard care plus a clinical pharmacological review, and standard care plus both combined. The trial ran May–December 2023 and was published in the Journal of Diabetology in October–December 2024 — a pilot-scale study at 30 patients per arm.

70.0%
Standard care alone (control)
73.1%
MedpeR® + standard care
75.3%
Clinical review + standard care
82.1%
MedpeR® + clinical review combined

What the results actually show

The honest read: MedpeR® alone improved adherence over standard care, but it wasn't the single biggest lever in the trial — the clinical pharmacological review arm outperformed it, and the combination of both performed best of all, at 82.1%. That's a more useful finding than a device claiming to fix adherence on its own — it suggests a device and a clinical review address different parts of the same problem, and work better together than either does alone.

The authors note this was a pilot-scale study (30 patients per arm) and that future research should assess more diverse populations and long-term sustainability — a normal next step for a trial at this stage, not a limitation specific to MedpeR®.

Why this matters for multi-drug chronic regimens

Diabetes rarely travels alone — hypertension, cardiac follow-ups, and other chronic conditions frequently mean four or five medications on overlapping schedules for the same patient. MedpeR® supports up to 9 compartments, 8 of which map to a specific medication and dose schedule — enough for most multi-drug chronic regimens without patients or caregivers needing to track a spreadsheet of timings by memory.

Citation: Samajdar SS, Tripathi R, Mukherjee S, Biswas K, Joshi SR, Sarkar S, Tripathi SK, Saboo B. Improving medication adherence in geriatric T2DM patients: A factorial randomized controlled trial. Journal of Diabetology 2024;15:389–94. DOI: 10.4103/jod.jod_85_24 · CTRI Registration: CTRI/2023/10/058703 · Ethics approval: HREC-AARC/33.

The full trial data, additional peer-reviewed literature discussing MedpeR® within the broader adherence-technology field, and conference abstracts from an earlier pilot evaluation are all available on our clinical evidence page, with citations and registration numbers included.

See the full clinical evidence, or evaluate MedpeR® for a chronic-care caseload

View Clinical Evidence → Evaluate for Your Facility →